

Microbe of the month


Breaking The Chain of Infection



OCTOBER 2023 NEWSLETTER

Compiled by
Helen Loudon IPC Consultant

[CLICK HERE TO DOWNLOAD](#)



Featured
this
month:

Staphylococcus aureus (S. aureus)

A master amongst microbes!

15-minute read + QUIZ

Hello readers!

Microbe of the Month aims to provide a concise clinical resource, to help you keep up to date about pathogens of importance, in an easy-to-read and understand format.

Each issue covers the aetiology (sources) and epidemiology of topical bacteria, viruses or fungi - their mode/s of transmission and the infections they cause; alerts on any antimicrobial resistance (AMR) capability they may have; and the relevant Infection Prevention and Control measures which should be routinely implemented for the safety of patients and healthcare personnel.

There is a quick quiz at the end of the newsletter to test your grasp of the content – please use this newsletter as a teaching tool in your workplace and start an ‘infectious dialogue’ about topical issues in infection control!

Staphylococcus aureus (pronounced ‘staf-ill-oh-KOK-us AW-ree-us’) is the obvious choice for this month’s issue, as we commemorate **World MSRA Day** (2nd October), **World Hand Hygiene Day** (15th October), **International Infection Prevention Week** (15th - 21st October) and **International Stop Wound Infection Day** (19th October).

S. aureus does not normally cause infection in healthy, intact skin; however, if it enters the tissues through a break in the skin, or is introduced into the bloodstream (e.g., via an intravenous catheter, or an endotracheal tube in ventilator-associated pneumonia), it becomes a highly successful **opportunistic pathogen** responsible for a large spectrum of infections, from superficial abscesses, boils and complicated wound infections to life-threatening infections such as osteomyelitis, pneumonia and septicaemia.

***S. aureus* is transmitted person-to-person by direct contact** (‘skin to skin’ contact, especially via hands) **or by contaminated objects** (fomites) **and surfaces.**¹⁻³

Key words: commensal, colonised, reservoir, carrier, contact transmission, healthcare-associated infection (HAI), antibiotic resistance, antimicrobial stewardship (AMS), infection control.

Staphylococcus aureus is major bacterial human pathogen and the most frequent cause of wound and healthcare-associated infections (HAIs)^{1,2}



EPIDEMIOLOGY OF STAPHYLOCOCCUS AUREUS INFECTION

Staphylococcus aureus is a Gram-positive bacterium found on the skin, mucous membranes and in the nares (nostrils) of healthy people and animals, who are generally referred to as 'carriers'. However, humans are the major **reservoir** – it is estimated that up to half of all adults are colonised with *S. aureus*, and at least 15% of the population persistently carry *S. aureus* in the anterior nares.²

The main mode of *S. aureus* transmission is primarily via hands, from 'high touch surfaces', and in crowded environments where the skin is exposed.

Some populations tend to have higher rates of *S. aureus* (and even MRSA) colonisation (as much as 80%), such as healthcare workers, individuals who use needles on a regular basis (i.e., diabetics and intravenous (IV) drug users), hospitalised patients, people living in communal accommodation (e.g., prisons, boarding schools, care homes), gym-goers and immunocompromised individuals.^{1,2,4}

What puts people at risk for serious staph infection?

In Communities	In Hospitals	In Other Healthcare Facilities
<ul style="list-style-type: none"> – Uncovered or draining wounds, especially in high-contact sports or crowded living – Sharing personal items, such as towels or razors – Recent stays in a healthcare facility – Injection drug use, like opioids 	<ul style="list-style-type: none"> – Hospital stays or surgery (during and shortly after) – Exposure to patients carrying or infected with staph – Medical devices in the body, like intravenous lines (IVs) 	<ul style="list-style-type: none"> – Outpatient surgery and procedures, like dialysis – Nursing home stays – Medical devices in the body, like IVs



Staphylococcus aureus ('*Staphylus*' is from the ancient Greek for 'grape cluster', and '*aureus*' – from the Latin for 'gold' – refers to the golden yellow colour of *S. aureus* colonies) is a Gram-positive (i.e., stained purple by Gram stain) bacterial **commensal**, commonly found in warm, moist areas of the body, particularly the nose, axilla, skin folds and perineum.




S. aureus possesses many **virulence factors** – including defensive proteins attached to its cell wall which interfere with the attack and phagocytosis by macrophages and neutrophils (white blood cells), as well as the production of highly toxic enzymes which cause acute physiological reactions (e.g., renal failure in septic shock).^{2,3}


Historically, certain strains of *S. aureus* quickly became resistant to penicillin until an alternative antibiotic – **methicillin** – was introduced in 1960. However, it wasn't long before resistant strains were again reported in 1962, which were associated with many serious hospital outbreaks.

Methicillin-resistant *Staphylococcus aureus* (MRSA) refers to a group of *Staphylococcal* bacteria that are genetically distinct from other strains of *S. aureus*. MRSA is any strain of *S. aureus* that has developed (through horizontal gene transfer and natural selection) multiple drug resistance to **beta-lactam antibiotics** (β -lactam antibiotics are a broad-spectrum group of penicillin derivatives such as Ampicillin and Amoxicillin, as well as the cephalosporins and carbapenems).


Methicillin (or cloxacillin) is therefore used as a screening tool in the microbiology laboratory for sensitivity / susceptibility testing – hence the acronym **MRSA**.^{3,4}



Electron microscope image depicting the grape-like clusters of *Staphylococcus aureus* (*S. aureus*).



Laboratory microscopy illustrating a positive Gram's stain (i.e., the purple clusters of *S. aureus*).



The golden yellow colonies of *Staphylococcus aureus* (*S. aureus*) growing on laboratory nutrient agar.



THE SPECTRUM OF SERIOUS INFECTIONS CAUSED BY *S. AUREUS*^{1,2}

- **Bacterial exotoxin mediated:** infectious endocarditis, sepsis, gastroenteritis, toxic shock syndrome.
- **Skin and soft tissue infections:** impetigo, boils, carbuncles, cellulitis, 'scalded skin syndrome' (newborn infants), severe wound and burns infections – all types.
- **Musculoskeletal complications:** osteomyelitis, septic arthritis, devastating prosthetic device infections.
- **Respiratory infections:** chronic rhinosinusitis, pneumonia, empyema.
- **Catheter / device-related infections:** urinary, central line associated bloodstream infections (CLA-BSI), ventilator associated pneumonia (VAP).

- ✓ Implement specific infection prevention and control strategies aimed at 'breaking the chain' of transmission. For example, the use of standard precautions irrespective of patients' diagnosis, contact precautions (gloves and disposable aprons), scrupulous hand hygiene and the application of 70% alcohol-based hand sanitisers, the frequent disinfection of stethoscopes, avoidance of neck ties, long sleeves, the wearing of wrist bands and watches, and loose / uncovered hair and braids.
- ✓ Avoid sharing patient equipment in high-risk clinical areas.
- ✓ Use a detergent-based hypochlorite solution for damp-dusting and environmental disinfection – especially 'high touch' surfaces.
- ✓ Handle and dispose of used linen carefully – never place linen on the floor or on adjacent surfaces, and never carry it against your clothing or through the ward!
- ✓ Implement the SSI and CLA-BSI prevention bundles and ensure strict adherence to pre-, peri- and post-operative infection prevention measures across multidisciplinary teams.
- ✓ Place patients who are colonised or infected with MRSA in isolation, or cohort (combined isolation) with other MRSA patients – provided they have no other infection/s.
- ✓ The routine 'screening' of healthcare workers for MRSA is not recommended. Rather, carry out *S. aureus* surveillance and be on the alert for clusters of *S. aureus* infection.
- ✓ The use of topical (intranasal) antimicrobials such as mupirocin can be used to eliminate nasal colonisation in some nasal carriers. However, its use is controversial, especially in view of increasing mupirocin resistance.
- ✓ If the source of MRSA is community-acquired, treating family and close contacts is recommended to prevent recolonisation.
- ✓ Wash your hands after handling pets.
- ✓ Monitor and control the inappropriate use of antimicrobial agents!



Supply the correct answer!

Question 1. The main route of transmission of *S. aureus* is via _____.

Question 2. *S. aureus* is commonly found in _____ and _____ areas of the body, particularly the nose, axilla, skin folds and perineum.

Question 3. *S. aureus* is the most common cause of _____ infections.

Question 4. Methicillin-resistant *S. aureus* (MRSA) is resistant to all _____ antibiotics.

Question 5. The wearing of wrist _____ and watches, and loose / uncovered _____ and braids should not be permitted, to prevent the transmission of *S. aureus* in healthcare facilities.



Scan this QR code and an Essity representative will contact you

REFERENCES

1. US Centers for Disease Control and Prevention (CDC). *Staphylococcus aureus* in Healthcare Settings. <https://www.cdc.gov/hai/organisms/staph.html>
2. Taylor TA, Unakal CG. *Staphylococcus aureus* Infection. (Updated 2023 Jul 17). StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK441868/> [Accessed 4.9.2023].
3. Tankeshwarin A. *Staphylococcus aureus*: Disease, Properties, Lab Diagnosis. (Updated September 8, 2022). Bacteriology https://microbeonline.com/staphylococcus-aureus-disease-properties-pathogenesis-and-laboratory-diagnosis/#google_vignette [Accessed 4.9.2023]
4. National Institute for Communicable Disease of South Africa (NICD). Methicillin-Resistant *Staphylococcus aureus* (MRSA). <https://www.nicd.ac.za/diseases-a-z-index/methicillin-resistant-staphylococcus-aureus-mrsa/> [Accessed 4.9.2023].
5. Petinaki E, Spiliopoulou I. Methicillin-resistant *Staphylococcus aureus* colonization and infection risks from companion animals: current perspectives. *Vet Med (Auckl)*. 2015 Nov 6;6:373-382. doi: 10.2147/VMRR.S91313. PMID: 30101122; PMCID: PMC6067666.
6. World Health Organisation (WHO). 2009 Guidelines on Hand Hygiene in Healthcare.
7. US Centers for Disease Control and Prevention (CDC) Healthcare Infection Control Practices Advisory Committee (HICPAC). 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings (Updated: July 2023).



Cutimed® is a registered trademark of BSN medical GmbH. / Sorbact® is a registered trademark of ABIGO Medical AB.

Name and business address: BSN Medical PTY (LTD) an Essity Company. **Co. Reg. No.** 2001/003941/07. 30 Gillitts Road, Pinetown 3610. Tel. No. +27 31 010 0522. Customer Specific Enquiries: +27 31 710 8038/8005. Email: medical.za@essity.com, www.essity.com. Further information available on request from Essity. 23_BSN164

Tork Clean Hands Training, now available on desktop



Our award-winning virtual training environment helps healthcare professionals improve their hand hygiene compliance anywhere, at any time to secure hand hygiene at every moment.

According to research, we remember 90% of what we learn when we simulate the real experience as opposed to just 10% of what we read*.

Try for free at tork.co.za/cleanhands

*Based on The Learning Pyramid



Think ahead.

Stand together against antimicrobial resistance



 **wound
warriors**

Sorbact® Technology dressings can form a valuable part of your **Antimicrobial Stewardship** strategy¹

Antimicrobial resistance is a heavy burden and optimal wound management is key in fighting it. Dedicated to improving wellbeing through leading hygiene and health solutions, Essity supports the antimicrobial stewardship initiative.

- Sorbact® Technology dressings reduce the bioburden in wounds²
- Effective against the WHO's top 5 pathogens, as shown in-vitro³
- Using Cutimed® Sorbact® for acute and hard-to-heal wounds supports Antimicrobial Stewardship (AMS)¹ as part of a multi-modal approach, in line with the Best Practice Statement for AMS Strategies⁴

Prevent and manage infected wounds with the unique Sorbact® Technology.



www.woundwarriors.co.za

Cutimed is a registered trademark of Essity. Sorbact is a registered trademark of ABIGO Medical AB.

1. Rippon MG, Rogers AA, et al. 2021. Antimicrobial stewardship strategies in wound care: evidence to support the use of dialkylcarbamoyl chloride (DACC)-coated wound dressings. J Wound Care. 30(4):284-296.
2. Gentili V, Gianesini S, et al. 2012. Panbacterial real-time PCR to evaluate bacterial burden in chronic wounds treated with Cutimed Sorbact. Eur J Clin Microbiol Infect Dis. 31(7):1523-1529. 3. Husmark J, Arvidsson A, et al. 2020. Antimicrobial effect of a DACC-coated bacteria-binding wound dressing against WHO pathogens. EWMA 2020. EPO06. 4. Wounds UK (2020) Best Practice Statement: Antimicrobial stewardship strategies for wound management. Wounds UK, London. 5. Mosti et al., Comparative study of two antimicrobial dressings in infected leg ulcers: a pilot study, Journal of Wound Care, 2015 Mar;24(3):121-2; 124-7



Cost-effective
surgical site infection prevention...

Proven infection management...

Physical microbe binding
technology...

Leukomed® Sorbact® Surgical site infection prevention

- Clinically significant 65% relative risk reduction of acquiring a surgical site infection post caesarean section¹
- Up to 57% cost reduction of SSI when treating caesarean sections, using NHS cost model²
- Effective reduction of the bacterial burden in critically colonised or locally infected wounds³

¹ Stanirowski J, Bizon M, Cendrowski K, et al (2016b) Randomized controlled trial evaluating dialkylcarbomyl chloride impregnated dressings for the prevention of surgical site infections in adult women undergoing caesarean section. Surg Infect (Larchmt) 17(4): 427-35

² Davies H, McMaster J, et al. Cost-effectiveness of DACC dressing to prevent SSI following caesarean section. Presented at Wounds UK, Harrogate, November 2018

³ Cutting K, Maguire J (2015) Safe bioburden management. A clinical review of DACC technology. Journal of Wound Care Vol 24, No 5

Essity, 30 Gillitts Road, Pinetown 3610. Phone: + 27 31 710 8111.
Email: medical.za@essity.co.za. www.medical.essity.co.za

 **essity** Leukoplast®,
an Essity brand

Sorbact® is a registered trademark of ABIGO Medical AB.

Leukomed®
by **Leukoplast®**